NCT01578499View on ClinicalTrials.gov

A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Participants With CD30-Positive Cutaneous T-Cell Lymphoma (ALCANZA Study)

PHASE3CompletedINTERVENTIONAL
Enrollment

131

Participants

Timeline

Start Date

June 11, 2012

Primary Completion Date

May 31, 2016

Study Completion Date

July 6, 2018

Conditions
Primary Cutaneous Anaplastic Large Cell LymphomaMycosis FungoidesCutaneous T-Cell Lymphoma
Interventions
DRUG

Brentuximab Vedotin

Brentuximab vedotin intravenous injection.

DRUG

Methotrexate

Methotrexate tablets.

DRUG

Bexarotene

Bexarotene tablets.

Trial Locations (41)

Unknown

Los Angeles

Palo Alto

Chicago

Boston

Hackensack

New York

Pittsburgh

Houston

Concord

South Brisbane

Adelaide

Nedlands

East Melbourne

Sankt Pölten

Vienna

Leuven

São Paulo

Nantes

Paris

Pessac

Pierre-Bénite

Reims

Kiel

Krefeld

Mainz

Mannheim

Minden

Würzburg

Bologna

Florence

Meldola

Warsaw

Pamplona

Barcelona

Madrid

Zurich

Leeds

Birmingham

Glasgow

London

Manchester

Sponsors
All Listed Sponsors
collaborator

Seagen Inc.

INDUSTRY

lead

Millennium Pharmaceuticals, Inc.

INDUSTRY

NCT01578499 - A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Participants With CD30-Positive Cutaneous T-Cell Lymphoma (ALCANZA Study) | Biotech Hunter | Biotech Hunter